JACC:TAVR术后的延迟性冠脉梗阻

2018-04-08 MedSci MedSci原创

延迟性冠脉梗阻(DCO)是经导管主动脉瓣置换术(TAVR)后较罕见的并发症。本研究的目的旨在评估TAVR术后DCO的发病率和病理生理学特征。本研究共纳入了2005年至2016年来自18个医学中心的17092名接受TAVR的患者,其中有38例患者出现了延迟性冠脉梗阻(0.22%)。DCO常在TAVR术后24小时内出现(47.4%; n = 18),6例DCO出现在术后24小时至7天内,剩下的14例出

延迟性冠脉梗阻(DCO)是经导管主动脉瓣置换术(TAVR)后较罕见的并发症。本研究的目的旨在评估TAVR术后DCO的发病率和病理生理学特征。

本研究共纳入了2005年至2016年来自18个医学中心的17092名接受TAVR的患者,其中有38例患者出现了延迟性冠脉梗阻(0.22%)。DCO常在TAVR术后24小时内出现(47.4%; n = 18),6例DCO出现在术后24小时至7天内,剩下的14例出现在术后60天以后。在患者出现的临床表现中,心脏停搏是最常见的(31.6%; n = 12),其次是ST段抬高型心肌梗死(23.7%; n = 9)。此外,左冠脉是最常见的梗塞冠脉(92.1%; n = 35),大多数梗塞患者都接受了经皮冠脉介入治疗(74.3%为左冠脉,60%为右冠脉)。院内总体死亡率为50% (n = 19),并且DCO发生在术后7天内的死亡率会更高(62.5% vs. 28.6%; p = 0.09)。

研究结果显示,延迟性冠脉梗阻是经导管主动脉瓣置换术后罕见的并发症,且院内死亡率较高。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086325, encodeId=6fa6208632539, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sat Jan 12 18:42:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853990, encodeId=cb0f1853990c0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 11 23:42:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325789, encodeId=2de51325e8927, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Apr 10 00:42:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303870, encodeId=f4ca3038e081, content=不错.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 08 10:54:29 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086325, encodeId=6fa6208632539, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sat Jan 12 18:42:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853990, encodeId=cb0f1853990c0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 11 23:42:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325789, encodeId=2de51325e8927, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Apr 10 00:42:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303870, encodeId=f4ca3038e081, content=不错.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 08 10:54:29 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-04-11 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086325, encodeId=6fa6208632539, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sat Jan 12 18:42:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853990, encodeId=cb0f1853990c0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 11 23:42:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325789, encodeId=2de51325e8927, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Apr 10 00:42:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303870, encodeId=f4ca3038e081, content=不错.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 08 10:54:29 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086325, encodeId=6fa6208632539, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sat Jan 12 18:42:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853990, encodeId=cb0f1853990c0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 11 23:42:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325789, encodeId=2de51325e8927, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Apr 10 00:42:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303870, encodeId=f4ca3038e081, content=不错.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 08 10:54:29 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-04-08 yydlt

    不错.学习了

    0

相关资讯

JAHA:NT‐proBNP在成年先心病患者中的预后价值

N末端B型利钠肽(NT‐proBNP)是成年先心病患者预后的可靠预测指标。本研究的目的旨在评估 NT‐proBNP在成年先心病患者中的水平以及其与心血管不良事件发生的相关性。本研究纳入了2011年至2013年门诊诊断的602名成年先心病患者,其中对595名(平均年龄为33岁,男性占58%,90%患者的纽约心功能分级为I级)患者的 NT‐proBNP水平进行了检测,并每年进行了随访,主要终点事件是死

Semin Arthritis Rheu:类风湿性关节炎、银屑病关节炎和银屑病预测心脏事件的心血管危险因素

女性RA患者和银屑病的额外心血管风险升高,而不是PsA。RA的全身炎症指标较高,而不是银屑病,表明这些病存在不同的心血管风险介质。

JACC:心衰与癌症的发生相关吗?

近期有研究表明,心衰患者发生癌症的风险要更高,然而这些研究的临床样本量较少,随访时间较短。本研究的目的旨在评估心衰是否与癌症及其相关死亡率相关。本研究纳入了2个1982年至1995年和1997年至2011年的内科医生健康调查随机临床对照研究,在初始分析时,研究者排除了一开始就有癌症或者心衰的患者,通过多变量调整Cox模型分析心衰与癌症发生的关系。在补充分析时,研究者纳入非癌症的70岁患者作为研究对

EPI|LIFESTYLE 2018 Scientific Sessions:服用抗生素>2月,心血管死亡风险增57%

美国Tulane大学的学者研究发现,长期服用抗生素的老年女性的死亡风险显著增加,尤其是心血管死亡风险增加57%。

NAT COMMUN:临床试验证明小分子可能改善心血管衰老

最近,来自科罗拉多大学博尔德分校的研究人员在一个2×6周的随机,双盲,安慰剂对照,交叉临床试验中找到了证据。

JAHA:慢阻肺患者SAVR和SAVR该如何选择?

慢性阻塞性肺疾病(COPD)患者在心脏手术后发生呼吸相关性并发症的风险更高。目前对于COPD患者,经导管主动脉瓣置换术(TAVR)和外科主动脉瓣置换术(SAVR)哪个预后更佳尚不清楚。本研究纳入了数据库中2011年至2014年年龄≥60岁,接受了TAVR或SAVR治疗的COPD患者,最终共纳入了相互匹配的1210名TAVR患者和1208名SAVR患者。分析结果显示,相比于接受SAVR患者,接受TA